Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy

[1]  M. Panasiuk,et al.  Immunization with Leishmania tarentolae-derived norovirus virus-like particles elicits high humoral response and stimulates the production of neutralizing antibodies , 2021, Microbial Cell Factories.

[2]  V. Young,et al.  Delivering Two Tumour Antigens Survivin and Mucin-1 on Virus-Like Particles Enhances Anti-Tumour Immune Responses , 2021, Vaccines.

[3]  Jenna A. Dombroski,et al.  Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response , 2021, Frontiers in Oncology.

[4]  P. Radhakrishnan,et al.  Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[5]  Qianhong Cen,et al.  A review on development of MUC1-based cancer vaccine. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  L. Bermudez,et al.  Investigating the Role of Mucin as Frontline Defense of Mucosal Surfaces against Mycobacterium avium Subsp. hominissuis , 2020, Journal of pathogens.

[7]  L. Vaca,et al.  Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs , 2020, Frontiers in Immunology.

[8]  F. Pericle,et al.  Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines , 2020, Viruses.

[9]  Xi Jiang,et al.  Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development , 2019, Pharmaceutics.

[10]  Doukas Anargyros,et al.  Heterologous expression of the mammalian sodium-nucleobase transporter rSNBT1 in Leishmania tarentolae. , 2019, Biochimica et biophysica acta. Biomembranes.

[11]  D. Speiser,et al.  Virus‐like particles for vaccination against cancer , 2019, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[12]  C. Ding,et al.  Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice , 2018, BMC Veterinary Research.

[13]  J. Kucharczyk,et al.  Targeting Toll-Like Receptors for Cancer Therapy , 2018, Targeted Oncology.

[14]  M. Vogel,et al.  Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System , 2018, Vaccines.

[15]  Li Nie,et al.  Toll-Like Receptors, Associated Biological Roles, and Signaling Networks in Non-Mammals , 2018, Front. Immunol..

[16]  M. Penichet,et al.  Virus-like particle display of HER2 induces potent anti-cancer responses , 2018, Oncoimmunology.

[17]  V. Ward,et al.  Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer , 2017, Journal of Immunotherapy for Cancer.

[18]  E. Schmitt,et al.  Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3‐Activating Adjuvant , 2017, ChemMedChem.

[19]  V. Apostolopoulos,et al.  Cellular Mucins: Targets for Immunotherapy. , 2017, Critical reviews in immunology.

[20]  W. Cao,et al.  An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[21]  D. Peabody,et al.  Engineering virus-like particles as vaccine platforms. , 2016, Current opinion in virology.

[22]  K. Bieńkowska-Szewczyk,et al.  Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus , 2016, Microbial Cell Factories.

[23]  A. Bolhassani,et al.  VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1. , 2015, Protein expression and purification.

[24]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[25]  R. Sodoyer.  Characterization and immunogenicity in mice of recombinant influenza haemagglutinins produced in Leishmania tarentolae , 2015 .

[26]  C. Batt,et al.  Secreted production of assembled Norovirus virus-like particles from Pichia pastoris , 2014, Microbial Cell Factories.

[27]  P. Mukherjee,et al.  MUC1: a multifaceted oncoprotein with a key role in cancer progression. , 2014, Trends in molecular medicine.

[28]  H. Frey,et al.  A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer. , 2014, Chemistry.

[29]  S. Bertholet,et al.  The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. , 2013, Vaccine.

[30]  H. Kunz,et al.  The development of synthetic antitumour vaccines from mucin glycopeptide antigens. , 2013, Chemical Society reviews.

[31]  E. De Gregorio,et al.  Vaccine Adjuvants: Mode of Action , 2013, Front. Immunol..

[32]  Kelly G Ten Hagen,et al.  Mucin-type O-Glycosylation during Development* , 2013, The Journal of Biological Chemistry.

[33]  E. De Gregorio,et al.  The mechanism of action of MF59 - an innately attractive adjuvant formulation. , 2012, Vaccine.

[34]  M. Wolfert,et al.  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine , 2011, Proceedings of the National Academy of Sciences.

[35]  J. Weidmann,et al.  Murine Polyomavirus Virus-Like Particles Carrying Full-Length Human PSA Protect BALB/c Mice from Outgrowth of a PSA Expressing Tumor , 2011, PloS one.

[36]  R. Rappuoli,et al.  Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88 , 2011, Proceedings of the National Academy of Sciences.

[37]  I. Bossis,et al.  Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles , 2010, Cancer Immunology, Immunotherapy.

[38]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[39]  G. Basile,et al.  Recombinant Protein Expression in Leishmania tarentolae , 2009, Molecular biotechnology.

[40]  V. Korolik,et al.  Mucins in the mucosal barrier to infection , 2008, Mucosal Immunology.

[41]  J. Mcghee,et al.  Host defenses at mucosal surfaces , 2008 .

[42]  V. Korolik,et al.  MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. , 2007, The Journal of clinical investigation.

[43]  Yue Wang,et al.  Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo. , 2007, Cellular immunology.

[44]  R. Cox,et al.  A Comparison of the Humoral and Cellular Immune Responses at Different Immunological Sites after Split Influenza Virus Vaccination of Mice , 2007, Scandinavian journal of immunology.

[45]  U. Karsten,et al.  What Makes MUC1 a Tumor Antigen? , 2005, Tumor Biology.

[46]  G. Forni,et al.  A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. , 2005, Cancer research.

[47]  M. Herrmann,et al.  Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma , 2005, Cancer Immunology, Immunotherapy.

[48]  L. Goulart,et al.  Is MUC1 polymorphism associated with female infertility? , 2004, Reproductive biomedicine online.

[49]  S. H. van der Burg,et al.  Identification of three non‐VNTR MUC1‐derived HLA‐A*0201‐restricted T‐cell epitopes that induce protective anti‐tumor immunity in HLA‐A2/Kb‐transgenic mice , 2001, International journal of cancer.

[50]  J. Taylor‐Papadimitriou,et al.  MUC1 and cancer. , 1999, Biochimica et biophysica acta.

[51]  P van Hoogevest,et al.  MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. , 1995, Pharmaceutical biotechnology.

[52]  J A Peterson,et al.  Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis. , 1992, The Journal of clinical investigation.

[53]  V. Wahn,et al.  Inhibition of adhesion of S-fimbriated Escherichia coli to buccal epithelial cells by human milk fat globule membrane components: a novel aspect of the protective function of mucins in the nonimmunoglobulin fraction , 1992, Infection and immunity.